2nd Quarter - Report
ROCK & ASSOCIATES for DIAMONDBACK DRUGS
Firm
Client
Income
$11,250
Expenses
—
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislation pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Budget/Appropriations BUD
Appropriations for FDA for FY2017 and FY2018. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Law Enforcement/Crime/Criminal Justice LAW
Controlled substance issues pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Pharmacy PHA
Legislation pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.